Search 

Clinical stage Biopharma

invest

MNC pharmaceuticals company

Founded in 2009 by Marc Andreessen and Ben Horowitz, Andreessen Horowitz (known as "a16z") is a venture capital firm in Silicon Valley, California, that backs bold entrepreneurs building the future through technology. We are stage agnostic: We invest in seed to late-stage technology companies, across the consumer, enterprise, bio/healthcare, crypto, and fintech spaces. a16z has nearly $16.5B in assets under management across multiple funds, including the $1.4B Bio funds, the $865M Crypto funds, and the Cultural Leadership Fund.

a16z is defined by respect for the entrepreneur and the entrepreneurial company building process; we know what it’s like to be in the founder’s shoes. The firm is led by general partners, many of whom are former founders/operators, CEOs, or CTOs of successful technology companies, and who have domain expertise ranging from biology to crypto to distributed systems to security to marketplaces to financial services.

We aim to connect entrepreneurs, investors, executives, engineers, academics, industry experts, and others in the technology ecosystem. We have built a network of experts including technical and executive talent; top media and marketing resources; Fortune 500/Global 2000 companies; as well as other technology decision makers, influencers, and key opinion leaders. a16z uses this network as part of our commitment to help our portfolio companies grow their business, so our operating teams provide entrepreneurs with access to expertise and insights across the entire spectrum of company building.

AnHeart Therapeutics is an oncology-focused clinical stage biopharmaceutical company headquartered in Hangzhou, China with offices in Beijing, Shanghai and New York. The company’s pipeline consists of three clinical stage assets: Taletrectinib, a next-gen ROS1 and NTRK inhibitor currently in Phase 2; an mIDH1 inhibitor ready for Phase 2 for low grade glioma, cholangiocarcinoma, AML and other tumors; and an AXL inhibitor in Phase 1 for overcoming resistance in various tumors.

Our mission is very simple: to use immunology to save the lives of the most vulnerable. Whether it’s the young who have yet to develop strong immune systems, the elderly who suffer from waning immune systems, or the immunocompromised whose immune systems are insufficient do to acquired medical conditions or the treatments thereof, Ansun’s mission is to discover and use novel approaches to develop therapies that prevent, treat, and cure some of the world’s most vexing human diseases. This has been our mission since 2003, when Ansun was formed for the purpose of developing a novel approach to treat otherwise untreatable pandemic flu strains (in fact, all flu strains), and it remains our mission today.

Health analytics

VC in Chicago